Deletion of EEPD1 reveals macrophage-specific changes in lipid metabolism and cholesterol efflux


Just in before the PhD defence, Suzanne latest publication on EEPD1 was accepted for publication in “Atherosclerosis” (https://www.atherosclerosis-journal.com/article/S0021-9150(25)00060-7/fulltext). This study describes the metabolic phenotype of mice and macrophages lacking EEPD1. This study reveals that mice lacking EEPD1 are susceptible to weight gain when challenged with a fat containing diet, cements the role of EEPD1 in cholesterol efflux, and identifies marked lipidomic changes in macrophages in the absence of EEPD1. 

Share this message

Latest news Medical Biochemistry Amsterdam

By duda-wsm June 17, 2025
Project MERCURY is taking off! Prof Noam Zelcer has been awarded an NWO open competition grant to study hepatic APOB metabolism and VLDL production. To do so, innovative proteomic and genetic approaches coupled to in vivo studies will be used to understand how APOB/VLDL is lipidated, trafficked, and secreted in hepatocytes.
By duda-wsm May 28, 2025
At the annual Dutch Atherosclerosis Society (DAS) meeting, Lobke received the award for Best Flash Talk for her presentation on the role of LXR in macrophage immune activation, while Ricky was awarded Best Poster Presentation for his work on the role of IRF1 in macrophage function. Congratulations to both!
Show More